Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Absztrakt
Leírás
Kulcsszavak
Forrás
Lancet Oncology. - 18 (2017), p. 297-311. -Lancet Oncol. - 1470-2045